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Abstract: Zinc finger protein 554 (ZNF554), a member of the Krüppel-associated box domain zinc
finger protein subfamily, is predominantly expressed in the brain and placenta in humans. Recently,
we unveiled that ZNF554 regulates trophoblast invasion during placentation and its decreased
expression leads to the early pathogenesis of preeclampsia. Since ZNF proteins are immensely
implicated in the development of several tumors including malignant tumors of the brain, here we
explored the pathological role of ZNF554 in gliomas. We examined the expression of ZNF554 at mRNA
and protein levels in normal brain and gliomas, and then we searched for genome-wide transcriptomic
changes in U87 glioblastoma cells transiently overexpressing ZNF554. Immunohistochemistry of
brain tissues in our cohort (n = 62) and analysis of large TCGA RNA-Seq data (n = 687) of control,
oligodendroglioma, and astrocytoma tissues both revealed decreased expression of ZNF554 towards
higher glioma grades. Furthermore, low ZNF554 expression was associated with shorter survival of
grade III and IV astrocytoma patients. Overexpression of ZNF554 in U87 cells resulted in differential
expression, mostly downregulation of 899 genes. The “PI3K-Akt signaling pathway”, known to be
activated during glioma development, was the most impacted among 116 dysregulated pathways.
Most affected pathways were cancer-related and/or immune-related. Congruently, cell proliferation
was decreased and cell cycle was arrested in ZNF554-transfected glioma cells. These data collectively
suggest that ZNF554 is a potential tumor suppressor and its decreased expression may lead to the
loss of oncogene suppression, activation of tumor pathways, and shorter survival of patients with
malignant glioma.
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1. Introduction
Zinc-finger proteins (ZNFs) belong to one of the largest transcription factor families in the
human genome showing a great diversity of molecular functions [1]. Notably, in addition to DNA
binding, studies have recently revealed the RNA, protein, and lipid interacting abilities of zinc finger
motifs [2–6]. Nearly one-third of ZNFs belong to the Krüppel-associated box domain zinc finger
protein (KRAB-ZNF) subfamily and contribute to transcriptional regulation during various cellular
processes including differentiation, cell growth, and morphogenesis [7–9]. The majority of KRAB-ZNFs
are involved in epigenetic silencing mediated by the KAP1 co-repressor via the induction of histone
H3K9 trimethylation and DNA methylation [10,11].
ZNF554, a member of the KRAB-ZNF subfamily, is encoded in the KRAB-ZNF cluster on
chromosome 19p13, which is highly coated by heterochromatin proteins and contains a large number
of long interspersed nuclear elements (LINEs), denoting the tightly controlled regulation of its
expression [12]. Surprisingly, our recent tissue qRT-PCR study revealed that ZNF554 gene expression
is mostly restricted to the brain and placenta in humans [13]. Furthermore, our genome-wide
transcriptomic analysis showed the emerging role of ZNF554 as a hub transcription factor that
drives deep trophoblast invasion, and the pathogenesis of preeclampsia is partly originated from its
dysregulation. As functional evidence, ZNF554-silenced extravillous trophoblast cells had reduced
migratory and invasive functions [13].
The remarkable ZNF554 expression in the brain [13] was particularly interesting since ZNFs play
a critical role in the development and differentiation of the nervous system. For instance, ZNF536
is abundant in the brain and is expressed in the developing central nervous system localized in
the cerebral cortex, hippocampus, and hypothalamic area. ZNF536 expression is increased during
cell differentiation and its overexpression inhibits retinoic-acid induced neuronal differentiation [14].
The importance of KRAB-ZNFs in the development and function of the brain is also supported by
an interesting study, where differential expression of genes among human and chimpanzee tissues
was compared. Nowick et al. found differential expression of 90 transcription factor genes only in the
brain and revealed that they are organized in a co-expression network comprised of two modules,
both enriched for primate-specific KRAB-ZNF genes [15].
Based on their essential role in transcription regulation, it is of major interest that many ZNF
proteins act either as oncogenes or tumor suppressors [5,16], and are immensely implicated in
the development of several tumors including gliomas [5]. Gliomas account for about 80% of all
malignant primary brain tumors [17]. According to the most recent WHO classification criteria [18],
most diffuse gliomas in adults belong to one of three molecular categories: Isocitrate dehydrogenase
(IDH)-wildtype, IDH-mutant but 1p/19q-non-codeleted, or IDH-mutant and 1p/19q-codeleted.
Histologically, 1p/19q-non-codeleted (IDH-wildtype or IDH-mutant) diffuse gliomas generally have an
astrocytic phenotype, and the IDH-mutant and 1p/19q-codeleted tumors possess an oligodendroglial
phenotype. Grade IV astrocytic glioma (glioblastoma multiforme (GBM)) is the most frequent adult
glioma type and has the lowest survival rate [19]. Regarding the role of ZNFs in the development of
gliomas, ZNF926 has been shown to promote cell proliferation and survival in gliomas [20], and stem
cell maintenance in GBM [21]. In addition, Tatard et al. concluded in their study that antiproliferative
functions of ZNF238 in normal granule neuron precursors and possibly other precursors counteract
brain tumors (medulloblastoma and glioblastoma) formation [22].
Since ZNF554 is a regulator of cell invasion [13], and it has high expression in the brain,
our collaborative teams [13,23,24] hypothesized that it may play a role in glioma development.
Accordingly, we aimed to examine the expression of ZNF554 both at RNA and protein levels in normal
brain and adult diffuse gliomas, as well as the association of ZNF554 expression with patient survival,
and to search for genome-wide transcriptomic and proteomic changes in glioblastoma cells transiently
overexpressing ZNF554. To our knowledge, this is the first study that unveils the detailed expression
pattern of ZNF554 in the human brain, the decreased expression of ZNF554 towards higher tumor
grades, and ZNF554 as a favorable prognostic gene in adult diffuse gliomas. We also show that
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ZNF554 overexpression in U87 glioblastoma cells leads to dysregulation of several pathways and genes
known to be impacted in adult diffuse gliomas. These results suggest that ZNF554 is a potential tumor
suppressor and its decreased expression may lead to the activation of tumor pathways in adult diffuse
gliomas, with a detrimental effect on patient survival.
2. Results
2.1. Brain Tissue Expression Pattern of ZNF554
Human tissue cDNA array expression profiling revealed that ZNF554 mRNA expression is
the highest in the brain amongst 47 human adult tissues included in the analysis [13]. In addition,
the second to fourth top tissues (spinal cord, optic nerve, retina), which have ca. 60% lower ZNF554
expression level than the brain, also belong to the nervous system (Supplementary Figure S1A).
When we took a closer look into the brain expression of ZNF554 using data from Allen Brain Atlas,
and we found that ZNF554 expression shows low region specificity. Only the white matter, striatum,
and the epithalamus had significantly lower (p < 0.05 or p < 0.01) ZNF554 expression than other brain
regions (Supplementary Figure S1B).
2.2. ZNF554 Protein Expression in Gliomas
Immunohistochemistry (IHC) results showed that ZNF554 protein expression decreased with
increasing tumor grades in patients with oligodendroglioma (ODG) and astrocytoma (AC). In detail,
average ZNF554 immunoscores were 33% and 47% lower in grade II and grade III ODG tumors,
respectively, than in controls (control: 3.00 ± 0.00; ODG grade II: 2.00 ± 0.26, p < 0.05; anaplastic ODG
grade III: 1.60 ± 0.22, p < 0.001, Figure 1A,B). In ACs, the average ZNF554 immunoscores were 40%
and 52% lower in grade III and grade IV tumors, respectively, than in controls (control: 3.00 ± 0.00;
anaplastic AC grade III: 1.80± 0.29, p < 0.05; GBM grade IV: 1.45± 0.25, p < 0.01, Figure 1A,B). The mean
immunoscore for ZNF554 was lower in grade II AC tumors as well, although the difference did not
reach statistical significance (2.40 ± 0.31, Figure 1A,B).
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Figure 1. Zinc finger protein 554 (ZNF554) expression is decreased at the protein level in gliomas.
(A) 5-µm-thick brain sections from controls (n = 11) and from patients with grade II (n = 10) or grade III
(n = 10) oligodendroglioma, grade II (n = 10) or grade III (n = 10) astrocytoma, or glioblastoma (n = 11)
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were immunostained for ZNF554. ZNF554 protein abundance decreased with increasing tumor
grades in patients with oligodendroglioma or with astrocytoma. Representative images, hematoxylin
counterstain, 50 µm scale bar, 400×magnifications. (B) ZNF554 immunoscores (mean ± SEM) of patient
groups are displayed on the left (control and oligodendrogliomas) and right (control and astrocytomas)
graphs. Kruskal–Wallis with Dunn’s post hoc test was used for the statistical analysis (* p < 0.05,
** p < 0.01, *** p < 0.001). Astrocytoma, AC; glioblastoma, GBM; oligodendroglioma, ODG.
2.3. ZNF554 mRNA Expression in Gliomas
Next, we aimed to confirm our findings at the mRNA level on larger cohorts. Therefore, we analyzed
ZNF554 mRNA expression in gliomas from the TCGA database [25]. We found that the ZNF554
log2 expression level was lower in all glioma groups (ODG grade II: 7.673 ± 0.027, ODG grade III:
7.659 ± 0.030, AC grade II: 7.579 ± 0.029, AC grade III: 7.458 ± 0.027, GBM: 7.241 ± 0.035, p < 0.001 in
all cases) compared to controls (8.272 ± 0.161, Figure 2A). Of note, there was no difference in ZNF554
expression in primary and recurrent gliomas Figure 2B). Furthermore, the survival probability of
patients with high ZNF554 expression was higher than those with low ZNF554 expression when all
gliomas were analyzed together (p < 0.001, Figure 2C). When gliomas were analyzed based on their
type and grade, low ZNF554 expression associated with shorter survival of anaplastic AC (grade III,
p < 0.05) and GBM (grade IV, p < 0.05) patients (including a subgroup of IDH-wildtype GBMs, p < 0.05),
but not with the survival of patients of the two ODG groups and the grade II AC group (Figure 2D–F).
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Figure 2. ZNF554 mRNA expression is decreased in gliomas and positively associates with patient
survival. (A) Box plots (median and whiskers: 1–99 percentile) represent normalized gene expression
levels (log2 norm_count+1) of ZNF554 from processed control brain (n = 5), ODG (grade II, n = 93;
grade III, n = 75, left graph), AC (grade II, n = 161; grade III, n = 194), and GBM (grade IV, n = 159,
right graph) RNA-Seq data from the TCGA database. One-way ANOVA with Dunnett’s post hoc test
(*** p < 0.001) was used to compare glioma groups with the control group. (B) In 20 cases (nODG = 3,
nAC = 11, nGBM = 6), ZNF554 gene expression levels of primary and recurrent gliomas were compared
by paired t-test and depicted on a before-after plot graph (ns: p > 0.05). Outcome predictions of all
gliomas (n = 682, C), ODG (grade II, (D) left graph), anaplastic ODG (grade III, (D) right graph),
diffuse AC (grade II, (E) left graph), anaplastic AC (grade III, (E) right graph), all (IDH-wildtype and
IDH-mutant) GBM (grade IV, (F) left graph), and IDH-wildtype GBM (grade IV, (F) right graph) cases
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based on TCGA overall survival data were linked to ZNF554 mRNA expression level. Kaplan–Meier
plots show survival correlations with high (red line) or low (blue line) expression levels of ZNF554.
The lower and upper quartiles of patients were analyzed by the Log-rank (Mantel-Cox) test (p < 0.05
was considered significant). Astrocytoma, AC; glioblastoma, GBM; isocitrate dehydrogenase, IDH;
oligodendroglioma, ODG.
2.4. The Effect of ZNF554 Overexpression in Glioblastoma Cells
To reveal the impact of ZNF554 expression on glioblastoma cells, we transiently overexpressed
ZNF554 in U87 glioblastoma cells. There was an average 92-fold increase in ZNF554 expression in
transfected cells compared to cells transfected with the empty vector (** p < 0.01, Figure 3A).
To further determine whether ZNF554 is a potential tumor suppressor in gliomas, the effect of
ZNF554 on proliferation/viability and cell cycle of U87 cells was examined. After transient transfection
with ZNF554, cell proliferation/viability decreased (p < 0.05, Figure 3B), and the number of U87 cells
in the G0/G1 phase slightly but significantly increased from 46.65% to 48.05% (p < 0.05, Figure 3C).
These results suggested that cell proliferation inhibition by ZNF554 is likely mediated through cell
cycle arrest at G0/G1.
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Figure 3. Overexpression of ZNF554 decreases cell proliferation and induces cell cycle arrest in U87
glioblastoma cells. (A) Box plots (median and whiskers: 1–99 percentile) represent the relative gene
expression level of ZNF554 in U87 cells two days after transient transfection with pCMV-ZNF554
or empty vector. Quantitative RT-PCR data are from five independent experiments. Unpaired
t-test with Welch correction was used for the statistical analysis (** p < 0.01). (B) Analysis of cell
proliferation/viability of vector- and ZNF554-transfected U87 cells by the Cell Counting Kit-8 assay.
The percentage of cell proliferation relative o the vector-transfected control cells are presented as the
mean ± SEM. (C) Analysis of cell cle distribution of vector- and ZNF554-transfected U87 cells by
Hoechst33342 staining and flow cytometry. Percentage of cells (mean ± SEM) in G0/G1, S, and G2/M
phases are shown. Data were retrieved from three-four independent experiments. Paired t-test was
used for the statistical analysis (* p < 0.05).
Genome-scale gene expression analysis identified dysregulation of 4.77% (899/18 834) of genes
expressed in U87 glioblastoma cells overexpressing ZNF554 (Supplementary Table S1, Figure 4A).
Of importance, the vast majority (84%, 754/899) of these genes were downregulated, which is
consistent with the overall repressive role of KRAB-ZNFs on gene transcription [8]. Among the
top 20 upregulated genes were several cytokines (IL6, interleukin 6; IL18, IL36B) and chemokines
(CCL20, C-C motif chemokine ligand 20; CCL5, CXCL2, C-X-C motif chemokine ligand 2), as well
as CDA (cytidine deaminase), CCDC134 (coiled-coil domain containing 134), and two HLA class
II major histocompatibility antigens (HLA-DRB3, HLA-DRB5). Among the top 20 downregulated
genes were a chemokine (CCL8), an integrin (ITGB1), two UDP-glucuronosyltransferases (UGT1A6,
UGT1A8), transcripts for several proteins found in the endoplasmic reticulum (SERP1, stress associated
endoplasmic reticulum protein 1; SEC23A, Sec23 homolog A, COPII coat complex component; TMED2,
transmembrane p24 trafficking protein 2), a proto-oncogene (CASC4, cancer susceptibility 4) and
Int. J. Mol. Sci. 2020, 21, 5762 6 of 18
IGFBP3 (insulin-like growth factor-binding protein 3). Of note, in the case of four genes selected for
validation, there was a good correlation between microarray and qRT-PCR results (Figure 4B).
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Figure 4. Genome-wide expression changes in U87 glioblastoma cells overexpressing ZNF554. (A) All
18,834 genes are represented in terms of their measured differences in abundance (x-axis) and the
significance of the difference (y-axis) on a volcano plot. The significance is represented as a negative
log (base 10) of the adjusted p-value so that more significant differences in expression are plotted
higher on the y-axis. Dotted lines represent the thresholds used to select the probes for differentially
expressed (DE) genes: <−1 and >1 for the magnitude of differential expression and pFDR of <0.1
for statistical significance. According to these criteria, of the 899 DE genes, 145 were up-regulated
(depicted with red), while 754 were down-regulated (depicted with dark green) in U87 cells transfected
with ZNF554. (B) Correlation of microarray and qRT-PCR results for the selected genes (ETS1, IGFBP3,
IL6, and ZNF554). The differences in the transcription of genes were log2-transformed and plotted
against each other. Statistical results of Pearson’s correlation are indicated (p < 0.05 was considered
significant). Two independent experiments in duplicates were performed. ETS proto-oncogene 1, ETS1;
insulin-like growth factor binding protein 3, IGFBP3; interleukin 6, IL6; positive false-discovery rate,
pFDR; zinc finger protein 554, ZNF554.
Analysis with iPathwayGuide to investigate biological processes and pathways dysregulated in
U87 glioblastoma cells overexpressing ZNF554 revealed that the most impacted Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathways included “PI3K-Akt signaling” and “proteoglycans in
cancer”, both cancer-related pathways (Supplementary Table S2, Figures 5A and 6). Among the
116 dysregulated pathways, 73 were cancer-related, 86 were immune-related, and 49 pathways were
common (Supplementary Table S2, Figure 5B).
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is overlaid with the computed log fold change of each gene. The downregulation is shown in dark
blue, and the upregulation in dark red. The legend describes values on the gradient. (B) Gene log
fold change bar plot. All genes in the PI3K-AKT signaling pathway were ranked according to log fold
change, negative values were depicted in blue and positive values in red. The box and whisker plot on
the left summarizes the distribution of all gene perturbations in this pathway, the box represents the
first quartile, median and third quartile, while circles represent outliers. Akt serine/threonine kinase,
Akt; phosphatidylinositol 3-kinase, PI3K.
Among 633 gene ontology (GO) biological processes dysregulated after positive false-discovery
rate (pFDR) correction, the most impacted were “phosphorus metabolic process”, “phosphate-containing
compound metabolic process”, “cellular response to chemical stimulus”, and “vesicle-mediated transport”
(Supplementary Table S3). We found the most impacted GO molecular functions to be “protein binding”,
“carbohydrate derivative binding”, “anion binding”, and “nucleotide binding” among 68 dysregulated
molecular functions (Supplementary Table S4).
3. Discussion
3.1. Principal Findings of This Study:
(1) ZNF554 shows predominant brain expression with low region specificity in humans; (2) in
adult diffuse gliomas, ZNF554 mRNA and protein expressions decrease with increasing tumor grade;
(3) low ZNF554 mRNA expression is associated with shorter survival of anaplastic astrocytoma and
glioblastoma patients, and also when all gliomas are analyzed together; (4) the overexpression of
ZNF554 results in the dysregulation of 899 genes in U87 glioblastoma cells, and most of these are
downregulated; (5) among 116 dysregulated pathways, 73 are cancer-related and 86 are immune-related
(49 pathways are common), and these are mostly downregulated; and (6) the overexpression of ZNF554
decreases cell proliferation and induces cell cycle arrest.
3.2. ZNFs in the Normal Human Brain
The largest TF family in mammals is the family of KRAB-ZNF genes, and about one-third of
these genes are primate-specific and evolved by recent gene duplications [26]. The rapid evolution
of these genes in the human lineage is also demonstrated by the fact that there is an enrichment of
KRAB-ZNF genes among DE genes in the human brain compared to chimpanzees [15]. Moreover,
among the ~350 KRAB-ZNFs expressed in humans, a larger number of KRAB-ZNFs are expressed
in the brain than in most other adult human tissues [9,27]. This evidence collectively suggests key
roles of KRAB-ZNFs in brain development and the expansion of higher brain functions in humans.
Of note, chromosome 19 contains the most KRAB-ZNF gene clusters, and ZNF554 is a member of
the chr19p13.3 gene cluster [28]. Our results showed that ZNF554 has predominant brain expression
among adult tissues with low region specificity. In a recent study, approximately 150 gene promoters
were counted as binding sites for ZNF554 in the brain, and its expression is constant in space and time
during neurodevelopment [29]. Besides ZNF554, Farmiloe et al. found that 50 other KRAB-ZNFs with
more than 50 binding sites on gene promoter regions are expressed in the human brain, and these TFs
can regulate gene expression in a region-specific manner during human brain development [29].
3.3. ZNFs are Double-Edged Swords in Different Cancer Types
We revealed decreased ZNF554 expression in adult diffuse gliomas with increasing tumor grade
at both protein and mRNA levels, which possibly reflects its tumor suppressor nature in gliomas.
Furthermore, lower ZNF554 expression was associated with worse prognosis in grade III ACs and
GBMs. Those patients having the worst survival outcomes (IDH-wildtype GBM) showed longer
overall survival with high ZNF554 expression. Interestingly, we found no apparent survival advantage
of high ZNF554 expression for ODGs or low-grade ACs. The reason for these differences remains to be
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determined, but the lack of a significant survival effect for ODGs may be explained, at least partly,
by the lower case numbers. Still, as Figure 2D demonstrates, high expressors in the Grade III ODG
group actually lived longer than the low expressors, and this difference may well become significant
in a larger cohort. For Grade II AC, the case numbers do not explain the lack of survival differences;
although there were a few very long survivors (>10 years) that were from the high expressor group.
ZNF671, also located on Chromosome 19, might play a tumor suppressor role in cancer since it was
found downregulated in eight cancer-related ZNF671 single-cell RNA-Seq datasets. The heterogeneous
functional states of cell subgroups and correlation analysis showed that ZNF671 played tumor
suppressor roles in heterogeneous cancer cell populations. Western blot and transwell assays identified
that ZNF671 inhibited epithelial-mesenchymal transition, migration, and invasion of central nervous
system cancers, lung cancer, melanoma, and breast carcinoma in vitro [30]. Interestingly, a recent
analysis of TCGA GBM samples [31] revealed that only 1.5% (3/201) of genes associated with unfavorable
prognosis in GBM are ZNF genes, while 18% (12/67) of genes associated with favorable prognosis in
GBM are ZNF genes. However, (KRAB-)ZNFs may be double-edged swords since they could act as both
tumor suppressors or oncogenes [5,32,33]. Even one ZNF can play different roles in different cancer
types and upon various stimuli. For example, ZNF395 expression is induced under hypoxic stress in
GBM, where it up-regulates interferon-stimulated and cancer-related genes, promoting inflammation
and cancer progression [34]. In contrast, the tumor suppressor role of ZNF395 was proven in liver
cancer, since the overexpression of miR-525-3p downregulated ZNF395, which promoted cancer cell
migration and invasion [35]. These studies collectively showed that ZNFs may play different roles in
different cancer types.
3.4. ZNF554 as a Potential Tumor Suppressor in Gliomas
To functionally investigate the potential tumor suppressor role of ZNF554 in gliomas, we performed
genome-wide expression profiling of U87 glioblastoma cells transiently overexpressing ZNF554 and
found that ZNF554 overexpression induced the upregulation of 145 genes and the downregulation of
754 genes. Functional analysis of these DE genes demonstrated a close correlation with cancer- and
immune-related pathways. The “PI3K-Akt signaling” was the most significantly enriched pathway,
and genes involved in this process included AKT1, JAK1, KRAS, MET, and PIK3R1. The PI3K-Akt
signaling pathway regulates various cellular processes such as cell cycle, apoptosis, and cytoskeletal
rearrangement [36]. This pathway can be activated by various growth factors, cytokines, chemokines,
hormones, extracellular matrix components, etc., through their respective receptors (e.g., RTKs,
cytokine receptors, GPCRs, adhesion molecules). It is located upstream to other pathways involved in
cancerogenesis (e.g., mTor, Ras, MAPK, FoxO, and insulin signaling pathways) [37–42] which were
also dysregulated in ZNF554-transfected cells. The importance of the PI3K-Akt signaling pathway
in glioma is proven by ongoing clinical trials in brain tumors targeting, amongst others, PI3K and
Akt [43,44]. Furthermore, we found decreased proliferation and cell cycle arrest of ZNF554-transfected
cells, which might be due to the downregulation of several cyclin-dependent kinases (CDK2, CDK9,
CDK10, CDK13, CDK17), and five (CCNC, CCND3, CCNE2, CCNG1, CCNG2) out of six cyclin genes.
This is in strong concordance with recent studies, one showing the anti-glioma effect of CDK inhibitors
already in preclinical/clinical use [45], the other finding several CDKs and cyclin genes amongst top
hub nodes in glioma network analysis [46].
Similar to our study, the enrichment of “allograft rejection”, “systemic lupus erythematosus”,
“graft-versus-host disease”, “type I diabetes mellitus”, “antigen processing and presentation”,
and “autoimmune thyroid disease” immune-related pathways were also found by Wang et al. analyzing
DE genes in glioblastoma [47]. It was suggested by others that enhanced HLA class II expression in
tumor cells may have significance in tumor immunogenicity, probably through enhanced direct tumor
cell killing [48]. In addition, downregulation of major HLA class I and II genes in migrating cells in vitro
and in invading cells in vivo was found in a glioma study [49].
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3.5. Potential Diagnostic and Therapeutic Implications of ZNF554 in Gliomas
Our results suggest that ZNF554 may be a novel prognostic biomarker for clinical patient
management, especially in those with grade III and IV gliomas. Future studies should evaluate if
low-grade gliomas lose ZNF554 as they undergo malignant transformation into high-grade gliomas.
Our in vitro studies suggest that enhanced expression of ZNF554 in such high-grade gliomas has the
potential to suppress tumor growth and invasiveness. Thus, the potential promotion of its expression
by gene therapy to restore ZNF554’s tumor suppressor effect may provide therapeutic advantages and
improve patient outcomes in adult diffuse gliomas. Such an effect would be particularly impactful in
patients with the worst prognosis and severe treatment resistance with the current therapeutic options,
such as those with IDH-wildtype GBM, where higher ZNF554 expression appeared to be beneficial for
survival. Delivery vectors such as viral vectors, liposomes, non-polymeric and polymeric nanoparticles
have been used in gene therapy of GBM [50]. For example, a Phase I clinical trial started in 1999 for
the treatment of recurrent malignant glioma with adenovirus-mediated p53 TF gene therapy [51].
However, later it was suggested to be effective as a supplementary therapy because of insufficient gene
transfer, lack of bystander effect, and tolerance arising from genetic heterogeneity of glioma [52,53].
Nevertheless, TFs have great potential as targets in the individualized therapeutic approaches to
cancer [54]. Moreover, a combination of various therapies, e.g., gene-and chemotherapy, gene-and
immunotherapy may further improve the effectiveness of glioma treatment.
3.6. Strengths and Limitations
The strengths of our study are as follows: (1) Strict clinical definitions and homogenous patient
groups; (2) the use of leading bioinformatics tools for microarray, gene ontology, and pathway analyses;
and (3) the immunohistochemical evaluation of a clinically and histologically well-characterized human
diffuse glioma collection.
Limitations of our study are as follows: (1) Due to the strict selection criteria, we could include
a relatively modest number of cases into the analysis of survival data, especially in some of the
glioma subgroups; (2) the number of samples was modest in the microarray and IHC experiments;
nevertheless, microarray results are meaningful and fit well with what was known about glioma
molecular development, while IHC results corroborate our findings on the large TCGA data set
showing decreased expression of ZNF554 at the mRNA level as well; and (3) we could only use a
glioblastoma cell line and not primary glioblastoma cells for the overexpression of ZNF554 since we
had no tissue source for primary cells. While U87 cells used in our study are among the most commonly
used glioma cell lines in neuro-oncology research, future studies could involve other glioma cell lines
to test baseline expression of ZNF554 and its expression in overexpression/siRNA systems.
4. Conclusions
ZNF554 is a potential tumor suppressor, and its decreased expression may lead to the loss of
oncogene suppression, activation of tumor pathways, and shorter survival in malignant glioma patients.
Although in vitro experiments were performed on an astrocytic glioma cell line, TCGA ZNF554 mRNA
expression data indicate the importance of ZNF554 in the pathophysiology of oligodendrogliomas as
well. ZNF554 overexpression in U87 glioblastoma cells induced gene expression changes associated
with cancer-and immune-related pathways, with the PI3K-Akt signaling pathway enriched most
significantly. Further studies, including single-cell RNA-seq analysis (with deep sequencing) on
normal and tumorous human brain, are required to understand the precise role of ZNF554 in brain
functions and oligodendroglial as well as astrocytic glioma development, and to reveal its diagnostic
and therapeutic potential in the prognostication and targeted therapy of adult diffuse glioma patients.
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5. Materials and Methods
5.1. Analysis of ZNF554 mRNA Expression in Normal Brain
Microarray data (Allen Human Brain Atlas data 2010 [55]) from six donors were downloaded
from http://human.brain-map.org in log2 format. The 169 different brain regions were grouped in 23
structural regions and ZNF554 expression levels (probe set ID: A_23_P343250) were visualized on a
bar chart.
5.2. Analysis of ZNF554 Protein Expression in Gliomas
Formalin-fixed paraffin-embedded (FFPE) brain biopsy specimens of 62 patients were studied
from the archives of the First Department of Pathology and Experimental Cancer Research,
Semmelweis University. Tumor tissues were classified according to the WHO classification of
Tumors of the Central Nervous System [18]. Based on the presence/absence of histological features,
diffuse gliomas, within oligodendroglial or astrocytic phenotype, are graded as WHO grade II
(low-grade), WHO grade III (anaplastic), or WHO grade IV (glioblastoma), the latter two referred to as
high-grade gliomas [56]. Permissions to use the archived tissues were obtained from the Local Ethics
Committee (TUKEB Approval No.: 155/2012) and the study was conducted in accordance with the
Declaration of Helsinki.
Fifty-one brain tumor tissues, including 10 cases of each diffuse astrocytoma (AC), anaplastic
AC, oligodendroglioma (ODG), anaplastic ODG, as well as 11 cases of GBM were selected for the
immunostaining. In addition, 11 samples of normal brain tissue, confirmed by histopathology,
from patients who underwent surgery for epilepsy were used as controls. Clinical information for
these patients is included in Table 1.
Table 1. Demographic and clinical characteristics of the immunohistochemistry study groups.
Groups Grade n a Age (Years) at Diagnosis a Male/Female b
Control (epilepsy) - 11 38.0 (14–64) 5/6
Oligodendroglioma II 10 51.5 (29–65) 3/7
Anaplastic oligondendroglioma III 10 47.0 (30–67) 3/7
Diffuse astrocytoma II 10 47.0 (29–69) 4/6
Anaplastic astrocytoma III 10 41.5 (31–78) 6/4
Glioblastoma multiforme IV 11 64.0 (24–73) 6/5
a Values are presented as numbers. b Values are presented as median (interquartile (IQR) range).
5.3. Immunohistochemistry for ZNF554
Five-micrometer-thick tissue sections were cut and mounted on SuperFrostTM Plus slides
(Thermo Fisher Scientific, Waltham, MA, USA) and stored at 4 ◦C until the staining. Immunostaining
was carried out using the Novolink Polymer Detection System (Leica-Novocastra, Nussloch, Germany)
according to the manufacturer’s protocol. Slides were dewaxed using xylene and rehydrated in
graded alcohol series. Endogenous peroxidases were blocked with 10%H2O2 in methanol (20 min,
room temperature). Antigen retrieval was performed at 37 ◦C for 5 min using the Bond Enzyme
Pretreatment Kit (Leica Biosystems). After blocking non-specific binding with the Novocastra Protein
Block (10 min, room temperature), slides were incubated with mouse polyclonal anti-ZNF554 antibody
(Abnova, Taipei, Taiwan) at 1:50 dilution overnight at 4 ◦C. After post-primary amplification (30 min,
room temperature), slides were incubated with the Novolink Polymer (30 min, room temperature) and
visualized with 3,3′-diaminobenzidine (DAB) for 10 min. Finally, sections were counterstained with
hematoxylin, and these were mounted (DPX Mountant; Sigma-Aldrich, St. Louis, MO, USA) after
dehydration. The primary antibody was omitted in negative controls.
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5.4. Evaluation of ZNF554 Immunostainings
Visual evaluation of ZNF554 immunostainings was performed microscopically (Carl Zeiss
Microscopy GmbH, Jena, Germany) by a pathologist (LR) blinded to the clinical data. The intensity
of the staining was recorded as absent, weak, moderate, or strong. The percentage of positive tumor
cells was scaled as follows: (i) Less than 10%, (ii) 10–50%, and (iii) more than 50% positive tumor cells.
ZNF554 protein expression was defined negative/weak (score 1) if less than 10% of the cells showed
any positivity; medium (score 2) if 10–50% of the cells showed any positivity or more than 50% of
the cells showed weak/moderate positivity; and high (score 3) if more than 50% of the cells showed
strong positivity.
5.5. Analysis of ZNF554 mRNA Expression and Patients’ Survival in Gliomas
Based on The Cancer Genome Atlas (TCGA) Lower-Grade Glioma and Glioblastoma Multiforme
study [57], normal brain, ODG (grades II and III), AC (grades II and III), and GBM (grade IV) ZNF554
RNA-Seq data were downloaded from the UCSC Xena platform [58] (https://xenabrowser.net/) in log2
normalized form (log2 norm_count+1). Data were filtered for patients with known ZNF554 expression
and survival data. Patients were reclassified according to the latest WHO glioma classification
criteria [18], based on molecular data. Finally, 687 patients (Supplementary Table S5) were included in
the analysis: normal brain (n = 5), ODG (grade II, n = 93), anaplastic ODG (grade III, n = 75), diffuse AC
(grade II, n = 161), anaplastic AC (grade III, n = 194), and GBM (grade IV, n = 159). ZNF554 expression
levels in different patient groups or primary and recurrent glioma cases (n = 20) were visualized on
box plots and before-after plots, respectively, using the GraphPad Prism 5 software.
Outcome predictions of all gliomas together, as well as grade II ODG, grade III ODG, grade II
AC, grade III AC, and grade IV GBM cases based on TCGA survival data linked to ZNF554 mRNA
expression level, were visualized on Kaplan–Meier plots with high or low. In the analysis, patients
with ZNF554 expression in the lower and upper quartiles were included.
5.6. Transient Transfection of U87 Glioblastoma Cells with ZNF554
Human U87 glioblastoma cells, obtained from the American Type Culture Collection (ATCC,
Manassas, VI, USA), were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-Thermo
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Gibco-Thermo Fisher) at
37 ◦C in a humidified 95% air and 5% CO2 atmosphere. Cells were transfected with expression
plasmid pCMV6-ZNF554 (OriGene, Rockville, MD, USA) or empty vector pCMV6 (OriGene) using
Lipofectamine-2000 (Thermo Fisher Scientific) following the manufacturer’s instructions. Transfection
media was replaced with fresh medium six hours post-transfection. Cells were split into two batches
24 h after transfection, harvested 48 h after transfection, washed twice with ice-cold Dulbecco’s PBS,
and then pellets were stored at −80 ◦C until use.
5.7. Total RNA Isolation
Total RNA was isolated from U87 cells by the Direct-zolTM RNA MiniPrep kit (Zymo Research,
Irvine, CA, USA) according to the manufacturers’ protocols. RNA concentrations were measured on a
NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific). RNA integrity and quality were
assessed on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). Isolated RNA was stored
at −80 ◦C until use.
5.8. Labeling and Microarray Hybridization
One microgram of total RNA was first reverse transcribed in 10 µL volume using Oligo(dT)
Primer and ArrayScriptTM enzyme (Thermo Fisher Scientific), then the second cDNA strand was
synthesized in 50 µL final volume using DNA Polymerase and RNase H (Thermo Fisher Scientific).
Amino allyl-modified antisense RNA (aaRNA) was then synthesized by in vitro transcription using
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amino allyl-modified UTP and T7 Enzyme mix. All these steps were done using the Amino Allyl
MessageAmpTM II aRNA Amplification Kit (Ambion-Thermo Fisher Scientific), according to the
manufacturer’s instructions. Six µg of amino allyl-modified amplified RNA was labeled with Cy3 dye
in 10 µL volume according to the manufacturer’s instructions (One-Color Quick Amp Labeling Kit,
Agilent Technologies) and purified with RNeasy Mini Kit (Qiagen). The incorporation rate of the dye
and the labeled aaRNA concentration were detected using NanoDrop 3.1.0. The incorporation rate of
the samples was 30–60 dye molecules per 1000 nucleotides.
The human oligonucleotide microarray (Whole Human Genome Microarray, 4 × 44 K, G2519F,
Design ID 014850, Agilent Technologies) was used to determine gene expression changes. 825 ng of
Cy3 labeled aaRNA, 11 µL 10X Blocking Agent and 2.2 µL 25X Fragmentation Buffer were mixed in a
final volume of 55 µL and fragmented at 60 ◦C for 30 min then 55 µL 2X GEx Hybridization Buffer were
added to each sample to stop the fragmentation reaction. All these steps were done using the Gene
Expression Hybridization Kit of Agilent Technologies according to the manufacturer’s instructions.
A hundred microliters of these mixes were used to fill the 4-plex backing slides and the microarray was
placed onto it. This “hybridization sandwich” was assembled in an Agilent microarray hybridization
chambers. The chambers were then loaded into a hybridization rotator rack (~5 rpm) and incubated at
65 ◦C for 17 h. After hybridization, the slides were washed in Wash buffer 1 at room temperature for
1 min then in Wash buffer 2 at 37 ◦C for another 1 min before scanning. Each array was scanned at
543 nm (for Cy3 labeling) in an Agilent Scanner (G2505B) using the extended dynamic range function
with 5µm resolution. Output image analysis and feature extraction were done using Feature Extraction
9.5.1 software using the single-color gene expression protocol (GE1_1100_Jul11) [59].
5.9. Quantitative Real-Time PCR
Five hundred nanograms of total RNA was transcribed by the qScript cDNA Synthesis kit
(Quantabio, Beverly, MA, USA). TaqManTM Gene Expression Assays (Table 2) and Universal PCR
Master Mix (Applied Biosystems-Thermo Fisher Scientific) were used for gene expression quantification
on a Biomark system (Fluidigm, San Francisco, CA, USA). Ct values for each target gene (ETS1, IGFBP3,
IL6, and ZNF554) and the endogenous control (RPLP0) were averaged over three technical replicates.
For each target gene, the fold change was calculated using the delta-delta Ct method. In the correlation
analysis, fold change data were log2 transformed.
Table 2. TaqMan assays used for qRT-PCR expression profiling.
Gene Symbol Gene Name Assay ID
ZNF554 Zinc finger protein 554 Hs00171072_m1
IL6 Interleukin 6 Hs00174131_m1
IGFBP3 Insulin-like growth factor-binding protein 3 Hs00181211_m1
RPLP0 Ribosomal protein lateral stalk subunit P0 Hs99999902_m1
5.10. Proliferation/Viability Assay
Forty-eight hours after transfection, the Cell Counting Kit-8 (Merck-Sigma Aldrich) colorimetric
assay was used to measure cell proliferation, according to the manufacturer’s instruction. The mean
optical density (OD at 450 nm) of three wells for the groups was used to calculate the percentage of cell
proliferation relative to the vector-transfected control cells.
5.11. Cell Cycle Assay
Forty-eight hours after transfection, 2.5 µg/mL Hoechst33342 (Thermo Fisher Scientific) was added
to the cells. Samples were incubated at 37 ◦C for 1 h then were trypsinized and measured on a Cytoflex
instrument (Beckman Coulter, Brea, CA, USA). Twenty thousand events were collected per sample.
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Late apoptotic/necrotic cells, stained by propidium iodide (Merck-Sigma Aldrich), were excluded from
the analysis.
5.12. Data Analysis
5.12.1. Allen Brain Atlas Data Analysis
Downloaded ZNF554 mRNA expression data were averaged to larger brain regions and statistical
analysis was performed by Kruskal–Wallis with Dunn’s post hoc test to compare the groups. p-values
of <0.05 were considered significant.
5.12.2. TCGA RNA-Seq Data Analysis
Downloaded data were filtered for ZNF554 expression in the normal brain and glioma tissues.
Mixed gliomas were excluded from the analysis. One-way ANOVA with Dunnett’s post hoc test was
used to compare glioma groups with the control group for ZNF554 expression. The paired t-test was
used to compare ZNF554 expression in primary and recurrent gliomas. The Log-rank (Mantel–Cox)
test was used for survival analysis. p-values of <0.05 were considered significant.
5.12.3. Microarray Data Analysis of Transfected U87 Cells
For U87 cells overexpressing ZNF554, analyses were performed in R statistical environment using
the limma package of Bioconductor (www.bioconductor.org). Following quality control performed
by arrayQualityMetrics [60], expression data were background corrected with the normexp method
and quantile normalized. Prior to differential gene expression analysis, irregular replicate probes
were averaged with avereps function of the limma package. Genes were selected as differentially
expressed upon a False Discovery Rate (FDR) [61] adjusted p-value of< 0.1 and fold-change of ≥2.
The hgug4112a.db Agilent whole-genome database was used for gene annotation.
5.12.4. Pathway Analysis
To identify significantly impacted pathways, biological processes, and molecular functions,
we compared gene expression between U87 cells transfected with an empty vector or with ZNF554
using Advaita Bio’s iPathwayGuide (https://www.advaitabio.com/ipathwayguide). This software
analysis tool implements the ‘Impact Analysis’ approach that takes into consideration the direction
and type of all signals on a pathway, the position, role, and type of every gene [62].
5.12.5. Quantitative RT-PCR Data Analysis
Unpaired t-test with Welch correction was used to compare the relative expression of ZNF554
between cells transfected with pCMV-ZNF554 vs. empty vector from five independent experiments.
Pearson’s correlation analysis was used to calculate the correlation strength and direction between
microarray and qRT-PCR data for the selected genes from two independent experiments. p-values of
<0.05 were considered significant.
5.12.6. Data Analysis of ZNF554 Immunostainings
Kruskal–Wallis with Dunn’s post hoc test was used to compare mean immunoscores between
control and patient groups. p-values of <0.05 were considered significant.
5.12.7. Data Analysis of Cell Proliferation/Viability and Cell Cycle
The paired t-test was used to compare proliferation (background-corrected optical density at
450 nm) or cell cycle status (percent of cells in G0/G1, S, and G2/M phases) of cells transfected with
pCMV-ZNF554 or empty vector from three-four independent experiments. p-values of <0.05 were
considered significant.
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